Categories Earnings

Novavax tumbles as net loss widened during 1Q

Shares of the synthetic vaccine maker Novavax (NVAX) tumbled about 6% during the extended hours trading session after the company reported a net loss during the first-quarter 2018 that widened to $46.4 million from $43.9 million a year earlier. On a per-share basis, the loss improved to 14 cents from 16 cents in the prior year. However, the company witnessed a whopping 70% jump in its revenue to $9.7 million. This huge lift was boosted by the higher revenue recorded under the BMGF grant relating to the ongoing Prepare clinical trial.

Novavax stock surged more than 70% during early April because of the acquisition rumors. There were speculations that the biotech firm would be acquired either by GlaxoSmithKline (GSK) or Sanofi (SNY).

It was said that both the companies eyed Novavax’s NanoFlu vaccine. In February, the company had offered positive top-line results from its Phase 1/2 clinical trial of NanoFlu, which has a tremendous opportunity if it goes through the clinical testing. Apart from experimental flu vaccine NanoFlu, the company has another candidate in pipeline i.e. the RSV F vaccine for infants via maternal immunization. The Gaithersburg-based vaccine company hopes to offer results on the Prepare Phase 3 interim efficacy analysis by early 2019.

Novavax is ambitious about its RSV F vaccine and hopes to generate sales of more than $1 billion from this vaccine alone. RSV F, if successful, could snatch the market share from Pfizer’s (PFE) Prevnar. The company recently made a stock offering to raise cash in order to fund the operations.

During the quarter, Novavax’s R&D expenses increased 18% to $44.5 million. The increase was primarily due to increased development activities of the RSV F Vaccine.

“We had an extremely productive first quarter, including making important advances in our two lead clinical vaccine programs. We are pleased to have reached the enrollment target for our Prepare Phase 3 RSV F Vaccine trial, which clears the path for following these most recent participants and their babies, and subsequently announcing top-line results of our planned interim efficacy analysis in the first quarter of 2019,” said CEO Stanley Erck.

 

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top